semaglutide hemodialysis pharmacokinetics in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study - Vanek - 2024 - Diabetes, Obesity and Metabolism Population Pharmacokinetics of Semaglutide for

Semaglutide and liraglutide serve as examples of GLP-1 receptor agonists, while sitagliptin and saxagliptin are commonly used DPP-4 inhibitors

Werden Ihre personenbezogenen Daten verarbeitet, um Direktwerbung zu betreiben, so haben Sie das Recht, jederzeit Widerspruch gegen die Verarbeitung Sie betreffender personenbezogener Daten zum Zwecke derartiger Werbung einzulegen

Transparent conversations with patients help address lingering concerns while highlighting the substantial benefits these medications can provide

Shown in a clinical study to naturally boost GLP-1 levels and keep them sustained: A hormone that signals fullness in the brain, helping to reduce cravings and support appetite regulation between meals

Straight-chain acyl-CoA oxidase knockout mouse accumulates extremely long chain fatty acids from alpha-linolenic acid: evidence for runaway carousel-type enzyme kinetics in peroxisomal beta-oxidation diseases

In 2025, it was also approved to treat chronic kidney disease in patients with Type 2 diabetes